Plasma arteriovenous cGMP difference as a useful indicator of nitrate tolerance in patients with heart failure.

Tsutamoto, Takayoshi; Kinoshita, Masahiko; Ohbayashi, Yasunori; Wada, Atsuyuki; Maeda, Yusaku; Adachi, Tsutomu

doi:10.1161/01.cir.90.2.823

Cited by 26 publications

(17 citation statements)

References 33 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inclusion of patients receiving nitrates may have influenced the results, since NO is a well‐known inducer of cGMP production. Second messenger cGMP production in response to NO is accomplished via soluble guanylyl cyclase receptors ,. More cases ( n = 12) than controls ( n = 5) were receiving nitrates, and we can speculate that this may have contributed to an underestimation of the cGMP response attenuation in the chronic advanced HF cases.…”

Section: Discussionmentioning

confidence: 97%

The cyclic guanosine monophosphate/B‐type natriuretic peptide ratio and mortality in advanced heart failure

Lourenço

Araújo

Azevedo

et al. 2009

European J of Heart Fail

View full text Add to dashboard Cite

AimsAttenuation of the effects of natriuretic peptides has been demonstrated in animal models but studies in humans are scarce, particularly concerning renal attenuation. We investigated the attenuation of B-type natriuretic peptide (BNP) in chronic advanced heart failure (HF). Methods and resultsWe included 62 outpatients with HF and severe left ventricular systolic dysfunction. Cases had at least one hospital admission or emergency department visit for acute HF in the previous year and were in NYHA class III/IV despite optimized therapy. The individual age-and sex-matched controls were symptomatically controlled (NYHA I and II). We collected 24 h urine and a blood sample from all patients. Plasma BNP and plasma (pcGMP) and urine cyclic guanosine monophosphate (ucGMP) were measured. Patients were followed for 3 months for hospital admission or all-cause death. ucGMP to plasma BNP (ucGMP/BNP) ratio was attenuated in cases vs. controls ConclusionRenal NP's second messenger production is attenuated in advanced HF. Patients with worse outcome have lower ucGMP/BNP and pcGMP/BNP ratios.--

show abstract

Section: Discussionmentioning

confidence: 97%

The cyclic guanosine monophosphate/B‐type natriuretic peptide ratio and mortality in advanced heart failure

Lourenço

Araújo

Azevedo

et al. 2009

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…16,41,42 These results underscore the physiological compartmentalization of the cGMP linked to either sGC or pGC cGMP signaling with differing cellular actions. [5][6][7][8][9][10]12,13 An additional finding was that M-ANP antagonized aldosterone activation despite continuous Ang II infusion. Most recently in a model of aldosterone-mediated glomerular injury, the GC-A receptor at the level of the glomerulus protected the glomerulus from structural remodeling 43 underscoring an important potential action of M-ANP if given long-term.…”

Section: Discussionmentioning

confidence: 99%

“…5,6 Furthermore, while both sGC and pGC activation results in the accumulation of cGMP within cells, pGC activation (in contrast to sGC) also results in significant release of cGMP into the extracellular space and circulation. [7][8][9][10][11] Therefore, while both sGC and pGC increase intracellular cGMP, the resulting biological actions are quite different. 4,12,13 Cyclic GMP therapies are currently employed in the treatment of heart failure (HF).…”

mentioning

confidence: 99%

M‐Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics

McKie

Cataliotti

Ichiki

et al. 2014

JAHA

View full text Add to dashboard Cite

BackgroundSystemic hypertension is a common characteristic in acute heart failure (HF). This increasingly recognized phenotype is commonly associated with renal dysfunction and there is an unmet need for renal enhancing therapies. In a canine model of HF and acute vasoconstrictive hypertension we characterized and compared the cardiorenal actions of M‐atrial natriuretic peptide (M‐ANP), a novel particulate guanylyl cyclase (pGC) activator, and nitroglycerin, a soluble guanylyl cyclase (sGC) activator.Methods and ResultsHF was induced by rapid RV pacing (180 beats per minute) for 10 days. On day 11, hypertension was induced by continuous angiotensin II infusion. We characterized the cardiorenal and humoral actions prior to, during, and following intravenous M‐ANP (n=7), nitroglycerin (n=7), and vehicle (n=7) infusion. Mean arterial pressure (MAP) was reduced by M‐ANP (139±4 to 118±3 mm Hg, P<0.05) and nitroglycerin (137±3 to 116±4 mm Hg, P<0.05); similar findings were recorded for pulmonary wedge pressure (PCWP) with M‐ANP (12±2 to 6±2 mm Hg, P<0.05) and nitroglycerin (12±1 to 6±1 mm Hg, P<0.05). M‐ANP enhanced renal function with significant increases (P<0.05) in glomerular filtration rate (38±4 to 53±5 mL/min), renal blood flow (132±18 to 236±23 mL/min), and natriuresis (11±4 to 689±37 mEq/min) and also inhibited aldosterone activation (32±3 to 23±2 ng/dL, P<0.05), whereas nitroglycerin had no significant (P>0.05) effects on these renal parameters or aldosterone activation.ConclusionsOur results advance the differential cardiorenal actions of pGC (M‐ANP) and sGC (nitroglycerin) mediated cGMP activation. These distinct renal and aldosterone modulating actions make M‐ANP an attractive therapeutic for HF with concomitant hypertension, where renal protection is a key therapeutic goal.

show abstract

“…Increased levels of plasma cGMP have been reported in several pathological situations including liver cirrhosis (17, 31, 32), cardiac diseases (33, 34) or pre‐eclampsia (35). Plasma cGMP levels are reduced during long‐term space flight (36).…”

Section: Discussionmentioning

confidence: 99%

Fine‐needle aspiration for nucleic acid‐ased molecular analyses in breast cancer

Uzan¹,

Varga²,

Scott³

et al. 2009

Cancer Cytopathology

View full text Add to dashboard Cite

BACKGROUND:With the widespread development of genomic analysis, an accurate and quick method for obtaining high-quality nucleic acids is needed. The objective of the current study was to evaluate the quality and potential use of material obtained from fine-needle aspiration cytology (FNAC). METHODS: Ultrasound-or palpation-guided FNAC was performed in 124 consecutive patients who had nodular breast lesions. The authors evaluated the amount of messenger RNA (mRNA) obtained, its quality through the RNA Integrity (RIN) score, and the factors that influenced both. For malignant lesions, the authors attempted to correlate estrogen receptor 1 (ESR1) and HER-2 (c-erb-B2) mRNA expression measured by real-time quantitative polymerase chain reaction with estrogen receptor and HER-2 detection obtained by immunohistochemistry (IHC) and/or fluorescent in situ hybridization (FISH) on the surgical specimen. RESULTS: The amount of mRNA obtained was >1 lg in 89.5% of 124 samples (43 benign lesions and 81 adenocarcinomas). Overall, 59.3% of samples yielded >1 lg RNA with a RIN score >6. The most significant predictors of quality and quantity of mRNA were the cytopathologist who sampled the tumors and a diagnosis of cancer versus benign lesion. The median ESR1 expression level, which was expressed as the polymerase chain reaction cycle threshold (CT) level minus the average 18S value (dct), was 17.7 dct in patients with estrogen receptor-negative tumors and 11.1 dct in patients with estrogen receptor-positive tumors,. The median HER-2 expression level was 15.1 dct in patients with HER-2-negative tumors and 10.7 dct in patients with HER-2-positive tumors. mRNA expression was concordant with the IHC/FISH evaluation in 90.3% of patients for estrogen receptor status and in 98.5% of patients for HER-2 status. CONCLUSIONS: In 70% of cases, FNAC of breast lesions in well trained hands allowed the extraction of mRNA suitable for gene expression analysis. Cancer (Cancer Cytopathol) 2009;117:32-9. V C 2009 American Cancer Society.KEY WORDS: breast cancer, fine-needle aspiration cytology, HER-2, estrogen receptor, gene expression.Fine-needle aspiration cytology (FNAC) or core-needle biopsy (CNB) of the breast can be performed easily on palpable tumors but requires the use of ultrasound (US) guidance for nonpalpable or deep-seated lesions. In some institutions, CNB is preferred, because it allows the study of a piece of tissue by most Original Article pathologists. However, when a trained cytopathologist is present and does the aspiration procedure with an on-site, immediate assessment, FNAC may help the clinician tremendously as a first step in triaging patients and selecting the best candidates for CNB. 1,2 An additional and emerging advantage of FNAC compared with CNB is its ability to obtain high percentages of tumor cells with much lower contamination of stromal cells for molecular analysis.For breast cancer, the use of genomic-based prognostic and predictive factors obtained before surgery is increasing, and a technique that can provide...

show abstract

Plasma arteriovenous cGMP difference as a useful indicator of nitrate tolerance in patients with heart failure.

Abstract: These findings indicate that the plasma arteriovenous cGMP difference is a clinical indicator of vasodilatory action of GTN and a useful indicator of nitrate tolerance in patients with CHF.

Cited by 26 publications

References 33 publications

The cyclic guanosine monophosphate/B‐type natriuretic peptide ratio and mortality in advanced heart failure

The cyclic guanosine monophosphate/B‐type natriuretic peptide ratio and mortality in advanced heart failure

M‐Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics

Fine‐needle aspiration for nucleic acid‐ased molecular analyses in breast cancer

Contact Info

Product

Resources

About